← Back to search
LUMEN BIOSCIENCE, INC
Doing business as LUMEN BIOSCIENCE
SEATTLE, WA, 98103
Unclaimed
Prime contracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | LUMEN BIOSCIENCE, INC. INTRANASAL ANTIBODY COCKTAIL DELIVERY PLATFORM AOI #6 BEYOND THE NEEDLE | — | $703,000 | Dec 20, 2022 | Apr 11, 2022 – Apr 30, 2023 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | DIARRHEAL DISEASES ARE A MAJOR CAUSE OF INFANT MORTALITY AND MORBIDITY IN THE DEVELOPING WORLD, WHERE TWO OF THE MAJOR CAUSAL PATHOGENS ARE CAMPYLOBACTER JEJUNI (C. JEJUNI) AND ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC). CURRENTLY, THERE ARE NO LICENSED VACCINES FOR THESE PATHOGENS. ANTIBIOTICS HAVE BEEN THE SOLE TREATMENT OPTION, LEADING TO THE EMERGENCE OF ANTIBIOTIC RESISTANCE. TO ADDRESS THIS NEED, LUMEN AIMS TO DEVELOP LMN-0403, AN ANTIBIOTIC-FREE, ULTRA-LOW-COST, COLD CHAIN INDEPENDENT, ORALLY DELIVERED, FOOD-GRADE THERAPEUTIC FOR PREVENTION AND TREATMENT OF DIARRHEAL DISEASES BY C. JEJUNI AND ETEC. LUMEN’S BIOLOGIC MANUFACTURING CAPABILITIES UTILIZE A SPIRULINA EXPRESSION SYSTEM TO PRODUCE A WIDE RANGE OF ANTIBODIES. THIS SYSTEM HAS THE POTENTIAL TO CREATE A THERAPEUTIC COSTING SUBSTANTIALLY LESS THAN 1 DOLLAR PER ADULT DOSE DUE TO MINIMAL DOWNSTREAM PROCESSING REQUIREMENTS. THE FINAL PRODUCT WILL CONSIST OF ORALLY DELIVERABLE SPIRULINA BIOMASS CONTAINING A COCKTAIL OF ANTIGEN-BINDING DOMAINS DERIVED FROM CAMELID SINGLE-CHAIN ANTIBODIES (VHHS) WHICH COVER AT LEAST 80% OF CLINICALLY RELEVANT C. JEJUNI AND ETEC STRAINS. THE WORK TO DATE IN DEVELOPING THIS PRODUCT UTILIZED BIOINFORMATICS TO IDENTIFY A MINIMAL SET OF TARGET VIRULENCE FACTORS; IDENTIFIED A SET OF VHHS THAT NEUTRALIZE THESE VIRULENCE FACTORS; OPTIMIZED THE VHHS BY LABORATORY SCALE EVOLUTION FOR BREADTH OF CROSS REACTIVITY TO REAL WORLD PATHOGEN VARIATION, FOR NEUTRALIZING POTENCY, FOR RESISTANCE TO GASTROINTESTINAL (GI) PROTEASES, AND FOR EXPRESSIVITY; CONSTRUCTED SPIRULINA STRAINS EXPRESSING THIS VHH COCKTAIL. IN THE PROPOSED WORK, THE PRODUCT WILL BE POSITIONED FOR EVALUATION IN A FIRST-IN-HUMAN (FIH) CLINICAL TRIAL. WE WILL ASSESS THE INCIDENCE OF DIARRHEAL DISEASE AND THE PATHOGEN VARIABILITY ENCOUNTERED BY THE POPULATION IN WHICH THE PRODUCT WILL BE CLINICALLY TESTED, TO ENSURE THAT THE CLINICAL STUDY IS ADEQUATELY POWERED AND THE VHH COCKTAIL IS SUITED FOR THIS STUDY POPULATION. WE WILL COMPLETE THE PRECLINICAL STUDIES TO ENABLE REGULATORY APPROVAL, MANUFACTURE CLINICAL TRIAL MATERIAL, AND OBTAIN REGULATORY APPROVAL FOR THE FIH STUDY. KC3391 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $1,065,478 | Oct 5, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced